Abstract

You have accessJournal of UrologyCME1 Apr 2023PD15-08 PROSTATE BED DEFORMATIONS AND DOSIMETRIC IMPLICATIONS: AN EXPLORATORY ANALYSIS OF A PHASE II CLINICAL TRIAL (SCIMITAR) Tommy Jiang, Lauren Smith, Luca Valle, Leslie Ballas, John Nikitas, Michael Steinberg, Robert Reiter, Minsong Cao, and Amar Kishan Tommy JiangTommy Jiang More articles by this author , Lauren SmithLauren Smith More articles by this author , Luca ValleLuca Valle More articles by this author , Leslie BallasLeslie Ballas More articles by this author , John NikitasJohn Nikitas More articles by this author , Michael SteinbergMichael Steinberg More articles by this author , Robert ReiterRobert Reiter More articles by this author , Minsong CaoMinsong Cao More articles by this author , and Amar KishanAmar Kishan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003262.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: One major challenge of postoperative radiotherapy is the deformable nature of the bladder and rectum. These changes can potentially lead to underdosing of the prostate bed and overdosing of the organs at risk (OARs: bladder and rectum). Our objective was to quantify the dosimetric impact of interfractional prostate bed and OAR deformation. METHODS: SCIMITAR (NCT03541850) was a prospective phase II clinical trial evaluating stereotactic body radiotherapy (SBRT) for post-prostatectomy patients. This analysis included men receiving CT-guided SBRT. All patients received five fractions of 6−6.8 Gy to the prostate bed. The clinical target volume (CTV) and OARs were retrospectively contoured on fractional CBCT images using MIMVista. Volumetric, shape (via the dice similarity coefficient [DSC]) and dosimetric changes were quantified. Student’s t-test was used to analyze the differences between planning and daily treatment outcomes RESULTS: 31 patients were eligible for this analysis. We found the CTV volume remained stable (median change 1.1%; IQR: -15.1%–16.1%), while the shape was highly deformable (DSC of 0.76 [IQR: 0.71–0.79]). The bladder and rectum exhibited similar changes with median volume change of 5.7% (IQR: -24.3%–51.0%) and 5.5% (IQR: -8.7%-21.9%) respectively and median DSC of 0.77 (IQR: 0.68–0.84) and 0.74 (IQR: 0.69–0.80) respectively. Notably, the CTV received less radiation than planned (volume receiving 95% of dose 93.2% vs 99.6%, p<0.01). Additionally, 39% (56/145) of total fractions and 52% (15/29) of patients met criteria for under coverage (volume receiving 95% of the dose <93%). The rectum received more radiation than planned on several dosimetric parameters (volume receiving 27.5 Gy increased from 15.4% to 21.0% [p = 0.009] and volume receiving 32.5 Gy increased from 6.0% to 10.9% [p = 0.006]) (Table 1). CONCLUSIONS: We found underdosing of the prostate CTV and overdosing of the rectum in a fair percentage of patients receiving postoperative radiation, despite modern radiotherapy planning and delivery techniques. While future work will correlate these dosimetric consequences with toxicity and efficacy, these data suggest that approaches to improving dose delivery, such as adaptive radiotherapy, may be beneficial. Source of Funding: AUA Medical Student Fellowship © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e421 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Tommy Jiang More articles by this author Lauren Smith More articles by this author Luca Valle More articles by this author Leslie Ballas More articles by this author John Nikitas More articles by this author Michael Steinberg More articles by this author Robert Reiter More articles by this author Minsong Cao More articles by this author Amar Kishan More articles by this author Expand All Advertisement PDF downloadLoading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.